- Active Pharmaceutical Ingredients
- 酒石酸伐尼克兰
- Aprepitant, Fosapitant Intermediates
- 福沙匹坦双葡甲胺
- 维格列汀
- 艾氟康唑
- Luliconazole Intermediate
- 钆特酸葡胺
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- 酒石酸伐尼克兰
- 阿瑞匹坦 287930-73-8
- 阿瑞匹坦 127852-28-2
- 阿瑞匹坦 287930-75-0
- 阿瑞匹坦 200000-59-5
- 阿瑞匹坦 155742-64-6
- 阿瑞匹坦 252742-72-6
- 福沙匹坦双葡甲胺 990-91-0
- 福沙匹坦双葡甲胺 265121-01-5
- 维格列汀 207557-35-5
- 维格列汀 702-82-9
- 艾氟康唑 144230-50-2
- 艾氟康唑 133775-25-4
- 艾氟康唑 127000-90-2
- 钆特酸葡胺
- 米拉贝隆
- 卢立康唑 98873-55-3
- 卢立康唑 126534-31-4
- 硫酸阿扎那韦
- 硼替佐米 179324-87-9
- 硼替佐米 114457-94-2
- 硼替佐米 205393-22-2
- 布林佐胺
- 利伐沙 446292-08-6
- 利伐沙 446292-07-5
- 西那卡塞 1005450-55-4
- 西那卡塞 585-50-2
- Eletriptan Intermediate
- 茚达特罗 312753-53-0
- 茚达特罗 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Rivaroxaban intermediate 446292-07-5
【Catalogue Number】AP8107
【CAS #】446292-08-6
【Molecular formula】C22H19N3O6
[Product Introduction] 2-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H -Isoindole-1,3(2H)-dione, English name is 2-[[(5S)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl ]-methyl]-1H-isoindole-1,3(2H)-dione, American Chemical Abstracts Registry number is cas 446292-08-6.
Alias Intermediate of Rivaroxaban
Catalog number AP8106
CAS # 446292-07-5
Molecular formula C22H19N3O6
Molecular weight 421.40
Structural formula
Product introduction
CAS 446292-07-5 2-[(2R) -2-hydroxy-3-[[4- (3-oxo-4-morpholinyl) phenyl] amino] propyl] -1H-isoindole- 1,3 (2H) -dione, English name 2-[(2R) -2-Hydroxy-3-[[4- (3-oxo-4-morpholinyl) -phenyl] amino] propyl]-
1H-isoindole-1,3 (2H) -dione, American Chemical Abstracts Registration Number is cas 446292-07-5.
2-[(2R) -2-hydroxy-3-[[4- (3-oxo-4-morpholinyl) phenyl] amino] propyl] -1H-isoindole-1,3 (2H) -Dione (CAS 446292-07-5) is an intermediate of rivaroxaban. Rivaroxaban is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation and reduce the risk of coronary artery recurrence.
VIWIT 沪ICP备12014533号-1
